HFB200301
hifibio
['hifibio']
#asco2022 is finally here! we are excited to share with the community how we have leveraged our dis approach to design our phase i for hfb200301, a first-in-class tnfr2 agonist monoclonal antibody. full abstract: #hifibioway #drugintelligentscience 
HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease.